IL148844A0 - Methods related to immunostimulatory nucleic acid-induced interferon - Google Patents
Methods related to immunostimulatory nucleic acid-induced interferonInfo
- Publication number
- IL148844A0 IL148844A0 IL14884400A IL14884400A IL148844A0 IL 148844 A0 IL148844 A0 IL 148844A0 IL 14884400 A IL14884400 A IL 14884400A IL 14884400 A IL14884400 A IL 14884400A IL 148844 A0 IL148844 A0 IL 148844A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- ifn
- nucleic acid
- methods related
- alpha
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 210000004544 dc2 Anatomy 0.000 abstract 3
- 230000004083 survival effect Effects 0.000 abstract 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010002386 Interleukin-3 Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15614799P | 1999-09-27 | 1999-09-27 | |
PCT/US2000/026527 WO2001022990A2 (fr) | 1999-09-27 | 2000-09-27 | Methodes concernant l'interferon induit par acides nucleiques immunostimulateur |
Publications (1)
Publication Number | Publication Date |
---|---|
IL148844A0 true IL148844A0 (en) | 2002-09-12 |
Family
ID=22558308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14884400A IL148844A0 (en) | 1999-09-27 | 2000-09-27 | Methods related to immunostimulatory nucleic acid-induced interferon |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1220684B2 (fr) |
JP (1) | JP2003510290A (fr) |
AT (1) | ATE333284T1 (fr) |
AU (1) | AU783118B2 (fr) |
CA (1) | CA2386019C (fr) |
DE (1) | DE60029460T3 (fr) |
ES (1) | ES2265980T5 (fr) |
IL (1) | IL148844A0 (fr) |
MX (1) | MXPA02003059A (fr) |
NZ (1) | NZ517928A (fr) |
WO (1) | WO2001022990A2 (fr) |
ZA (1) | ZA200201959B (fr) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0855184A1 (fr) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination |
DK2204186T3 (en) | 1999-02-17 | 2016-07-18 | Csl Ltd | Immunogenic complexes, and related methods |
EP1176966B1 (fr) | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Un oligodesoxynucleotide et son emploi pour induire une reponse immunitaire |
WO2001012223A2 (fr) | 1999-08-19 | 2001-02-22 | Dynavax Technologies Corporation | Procedes de modulation d'une reponse immunitaire par utilisation de sequences immunostimulantes et compositions utilisees |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
ATE378348T1 (de) | 2000-01-14 | 2007-11-15 | Us Health | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
EP1253947A4 (fr) | 2000-01-31 | 2005-01-05 | Univ California | Polynucleotides immunomodulateurs dans le traitement d'une infection par un pathogene intracellulaire |
AU2001241751B2 (en) | 2000-02-23 | 2005-09-01 | Tel Aviv Sourasky Medical Center | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
JP5059271B2 (ja) | 2000-03-31 | 2012-10-24 | パーデュー・リサーチ・ファウンデイション | リガンド免疫原複合体を用いる処置方法 |
JP2005500806A (ja) | 2000-09-15 | 2005-01-13 | コーリー ファーマシューティカル ゲーエムベーハー | CpGに基づく免疫アゴニスト/免疫アンタゴニストの高スループットスクリーニングのためのプロセス |
EP1364010B1 (fr) | 2000-12-27 | 2010-06-16 | Dynavax Technologies Corporation | Polynucleotides immunomodulants et methodes d'utilisation correspondantes |
KR20020083634A (ko) * | 2001-04-27 | 2002-11-04 | 크레아젠 주식회사 | 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법 |
CN100334228C (zh) | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | 嵌合免疫调制化合物及其使用方法 |
CA2456328C (fr) | 2001-08-07 | 2015-05-26 | Dynavax Technologies Corporation | Complexes d'oligonucleotide contenant du cpg a chaine courte lies a la surface d'une microbarriere en phase solide et ses methodes d'utilisation |
PT1446162E (pt) | 2001-08-17 | 2009-01-27 | Coley Pharm Gmbh | Agrupamentos imunoestimuladores oligonucléotidos com actividade melhorada |
EP2196217A1 (fr) | 2001-09-14 | 2010-06-16 | Cytos Biotechnology AG | Emballage de substances immunostimulantes dans des particules similaires aux virus: procédés de production et utilisations |
ES2338305T3 (es) * | 2001-09-28 | 2010-05-06 | Purdue Research Foundation | Metodo de tratamiento que utiliza conjugados ligando-inmunogeno. |
JP4846200B2 (ja) | 2002-04-04 | 2011-12-28 | コーリー ファーマシューティカル ゲーエムベーハー | 免疫賦活性g、u含有オリゴリボヌクレオチド |
JP2006515266A (ja) * | 2002-04-22 | 2006-05-25 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用 |
CA2388049A1 (fr) * | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Oligonucleotides immunostimulateurs et utilisations connexes |
JP2005532067A (ja) * | 2002-07-03 | 2005-10-27 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 刺激性免疫応答用の核酸組成物 |
AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
SG166673A1 (en) * | 2002-08-19 | 2010-12-29 | Coley Pharm Group Inc | Immunostimulatory nucleic acids |
ZA200503511B (en) | 2002-10-29 | 2006-10-25 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
US7758876B2 (en) | 2002-11-01 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
KR101178816B1 (ko) | 2002-12-23 | 2012-09-07 | 다이나박스 테크놀로지 코퍼레이션 | 면역자극성 서열 올리고뉴클레오타이드 및 이의 이용방법 |
CA2517839A1 (fr) | 2003-03-26 | 2004-10-07 | Martin F. Bachmann | Conjugues de particules d'aspect viral d'analogues du peptide melan-a |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
WO2004094448A1 (fr) * | 2003-04-23 | 2004-11-04 | Taisho Pharmaceutical Co. Ltd. | Polynucleotide cpg methyle |
CN1798563A (zh) * | 2003-05-15 | 2006-07-05 | 独立行政法人科学技术振兴机构 | 免疫刺激剂 |
JP3976742B2 (ja) | 2004-02-27 | 2007-09-19 | 江守商事株式会社 | インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド |
KR100958505B1 (ko) | 2004-07-18 | 2010-05-17 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제 |
JP2008000001A (ja) * | 2004-09-30 | 2008-01-10 | Osaka Univ | 免疫刺激オリゴヌクレオチドおよびその医薬用途 |
DE102005005642A1 (de) * | 2005-02-06 | 2006-08-10 | Phenion Gmbh & Co. Kg | Kosmetische oder pharmazeutische Zubereitungen enthaltend Nukleinsäuren, die zur Ausbildung von stem-loop-Sekundärstrukturen geeignete Sequenzen umfassen |
JP2008535862A (ja) | 2005-04-08 | 2008-09-04 | キメリクス,インコーポレイテッド | ポックスウイルス感染の治療のための化合物、組成物および方法 |
PL2179737T3 (pl) | 2005-07-01 | 2014-01-31 | Index Pharmaceuticals Ab | Sposób do modulowania wrażliwości na steroidy |
US8258107B2 (en) | 2005-07-01 | 2012-09-04 | Index Pharmaceuticals Ab | Immunostimulatory method |
WO2007027718A1 (fr) * | 2005-08-31 | 2007-03-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Procedes d'alteration d'une reponse immune induite par des cpg oligodeoxynucleotides |
WO2007050034A1 (fr) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition et procede pour la prevention, le traitement et/ou l’attenuation d’une maladie inflammatoire |
BRPI0618857B1 (pt) | 2005-11-25 | 2022-07-19 | Zoetis Belgium S.A | Oligonucleotídeo de rna isolado, e método para regular negativamente células reguladoras cd4+ imunossupressoras |
RU2451523C2 (ru) | 2005-12-14 | 2012-05-27 | Цитос Биотехнологи Аг | Упакованные иммуностимулирующей нуклеиновой кислотой частицы, предназначенные для лечения гиперчувствительности |
WO2007092299A2 (fr) | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Conjugués ciblés et radiation |
CN101460620B (zh) | 2006-05-31 | 2012-02-15 | 东丽株式会社 | 免疫刺激寡核苷酸及其药物用途 |
WO2007144150A1 (fr) | 2006-06-12 | 2007-12-21 | Cytos Biotechnology Ag | Procédé pour le conditionnement d'oligonucléotides dans des particules analogues à des virus de bactériophages à arn |
SI2056845T1 (en) | 2006-08-08 | 2018-02-28 | Rheinische Friedrich-Wilhelms-Universitaet Bonn | STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES |
CN101517082B (zh) | 2006-09-27 | 2014-01-22 | 科勒制药有限责任公司 | 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物 |
EP2338499A1 (fr) | 2006-10-10 | 2011-06-29 | Gunther Hartmann | Oligonucleotide 5'triphosphate induisant une réaction antivirale |
RU2009115687A (ru) * | 2006-10-26 | 2010-11-10 | Коли Фармасьютикал Гмбх (De) | Олигорибонуклеотиды и их применения |
AU2007333147B2 (en) | 2006-12-12 | 2013-12-19 | Kuros Us Llc | Oligonucleotides containing high concentrations of guanine monomers |
EP2160199A2 (fr) | 2007-05-17 | 2010-03-10 | Coley Pharmaceutical Group, Inc. | Oligonucléotides de classe a présentant une puissance immunostimulante |
DK2170353T3 (en) | 2007-05-18 | 2015-07-27 | Adiutide Pharmaceuticals Gmbh | The phosphate-modified oligonucleotide analogs with immunostimulatory activity |
DE102007044093A1 (de) * | 2007-09-14 | 2009-03-19 | Phenion Gmbh & Co. Kg | Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Induktion antimikrobieller Peptide in epithelialen Deckgeweben |
KR20100068422A (ko) | 2007-10-09 | 2010-06-23 | 콜리 파마슈티칼 게엠베하 | 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체 |
EP2254582B1 (fr) | 2008-01-25 | 2016-01-20 | Chimerix, Inc. | Méthodes de traitement d'infections virales |
EP2297323A1 (fr) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | Oligonucléotide à 5 -triphosphate présentant une extrémité franche et ses utilisations |
CA2737352C (fr) | 2008-10-16 | 2017-06-27 | University Of Saskatchewan | Formulation d'adjuvant de combinaison |
WO2010049438A2 (fr) * | 2008-10-30 | 2010-05-06 | Innate Pharma | Procédés améliorés d’utilisation de phosphoantigènes pour le traitement de maladies |
BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
EP2376108B1 (fr) | 2008-12-09 | 2017-02-22 | Pfizer Vaccines LLC | Vaccin peptidique de ige ch3 |
BRPI1014494A2 (pt) | 2009-04-30 | 2016-08-02 | Coley Pharm Group Inc | vacina pneumocócica e usos da mesma |
CA2767253A1 (fr) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Nouveaux precurseurs d'acide nucleique et leurs methodes d'utilisation |
SG10201401516XA (en) | 2009-09-03 | 2014-10-30 | Pfizer Vaccines Llc | Pcsk9 vaccine |
HUE032860T2 (en) | 2010-02-12 | 2017-11-28 | Chimerix Inc | A method for treating a virus infection |
US9278135B2 (en) | 2010-04-26 | 2016-03-08 | Chimerix Inc. | Methods of treating retroviral infections and related dosage regimes |
NZ603527A (en) | 2010-05-28 | 2014-10-31 | Zoetis Belgium S A | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules |
CA2800774A1 (fr) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Vaccin peptidique ige ch3 |
WO2012039448A1 (fr) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | Groupe auxiliaire asymétrique |
US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
EP2508530A1 (fr) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification d'oligonucléotides triphosphorylés au moyen d'étiquettes de capture |
WO2012167053A1 (fr) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Nouveaux modulateurs du système immunitaire |
RU2606114C2 (ru) | 2011-06-01 | 2017-01-10 | Джейнус Байотерапьютикс, Инк. | Новые модуляторы иммунной системы |
WO2013007703A1 (fr) | 2011-07-08 | 2013-01-17 | Universität Zürich | Oligonucléotides cpg de classe a pour la prévention d'une infection virale chez des chats |
EP2734208B1 (fr) | 2011-07-19 | 2017-03-01 | Wave Life Sciences Ltd. | Procédés pour la synthèse d'acides nucléiques fonctionnalisés |
WO2013052550A2 (fr) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline |
KR20220139425A (ko) | 2012-07-13 | 2022-10-14 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
CA2879066C (fr) * | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucleique chiral |
WO2014010250A1 (fr) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Groupe auxiliaire asymétrique |
EP2712870A1 (fr) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Nouveaux ligands de RIG-I et procédés pour les produire |
EP3095459A4 (fr) * | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral |
WO2015108046A1 (fr) * | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Adjuvant d'acide nucléique chiral ayant une activité anti-allergique, et agent anti-allergique |
EP3095461A4 (fr) * | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité |
MY193116A (en) | 2014-01-16 | 2022-09-26 | Wave Life Sciences Ltd | Chiral design |
WO2015123291A1 (fr) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin |
CN106535876B (zh) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用 |
EP3398948A3 (fr) | 2014-08-22 | 2018-12-05 | Janus Biotherapeutics, Inc. | Dérivés de ptéridine 2,4,6,7-tétrasubstituée et leurs procédés de synthèse et d'utilisation |
WO2017121494A1 (fr) * | 2016-01-15 | 2017-07-20 | Riboxx Gmbh | Nucléotides, oligonucléotides et polynucléotides immunostimuleurs courts 5'-triphosphatés |
EP3452598A4 (fr) | 2016-05-06 | 2020-04-29 | Exicure, Inc. | Constructions d'acides nucléiques sphériques liposomales (sna) présentant des oligonucléotides antisens (aso) pour l'inactivation spécifique de l'arnm du récepteur de l'interleukine 17 |
US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
CN109562122A (zh) | 2016-06-03 | 2019-04-02 | 波涛生命科学有限公司 | 寡核苷酸、组合物及其方法 |
CN108567977B (zh) * | 2017-03-13 | 2022-04-12 | 复旦大学 | 一种免疫增强剂、免疫治疗药物组合物及其制备与用途 |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
WO2019115385A1 (fr) * | 2017-12-15 | 2019-06-20 | Bayer Animal Health Gmbh | Compositions immunostimulantes |
WO2019173438A1 (fr) | 2018-03-06 | 2019-09-12 | Stc. Unm | Compositions et méthodes pour faire baisser les triglycérides sériques |
US20210261964A1 (en) * | 2018-07-19 | 2021-08-26 | The Research Foundation For Microbial Diseases Of Osaka University | LIPID PARTICLE CONTAINING A-TYPE CpG OLIGODEOXYNUCLEOTIDE |
EP3909612A1 (fr) | 2020-05-12 | 2021-11-17 | Life Science Inkubator Betriebs GmbH & Co. KG | Composition de nanoparticules |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0855184A1 (fr) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination |
GB9702021D0 (en) * | 1997-01-31 | 1997-03-19 | Imperial College | Medicaments |
WO1998052581A1 (fr) * | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vecteurs et procedes destines a l'immunisation et a des protocoles therapeutiques |
DE69935507T2 (de) * | 1998-04-03 | 2007-12-06 | University Of Iowa Research Foundation | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
WO2000006588A1 (fr) * | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREO-ISOMERES D'OLIGONUCLEOTIDES DE TYPE CpG ET PROCEDES CONNEXES |
-
2000
- 2000-09-27 NZ NZ517928A patent/NZ517928A/en not_active IP Right Cessation
- 2000-09-27 ES ES00965477T patent/ES2265980T5/es not_active Expired - Lifetime
- 2000-09-27 CA CA2386019A patent/CA2386019C/fr not_active Expired - Fee Related
- 2000-09-27 EP EP00965477A patent/EP1220684B2/fr not_active Expired - Lifetime
- 2000-09-27 AT AT00965477T patent/ATE333284T1/de not_active IP Right Cessation
- 2000-09-27 WO PCT/US2000/026527 patent/WO2001022990A2/fr active IP Right Grant
- 2000-09-27 JP JP2001526199A patent/JP2003510290A/ja active Pending
- 2000-09-27 AU AU76190/00A patent/AU783118B2/en not_active Ceased
- 2000-09-27 DE DE60029460T patent/DE60029460T3/de not_active Expired - Lifetime
- 2000-09-27 MX MXPA02003059A patent/MXPA02003059A/es active IP Right Grant
- 2000-09-27 IL IL14884400A patent/IL148844A0/xx unknown
-
2002
- 2002-03-08 ZA ZA200201959A patent/ZA200201959B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2386019A1 (fr) | 2001-04-05 |
DE60029460T3 (de) | 2011-02-10 |
MXPA02003059A (es) | 2002-09-30 |
DE60029460T2 (de) | 2007-03-15 |
ES2265980T3 (es) | 2007-03-01 |
ZA200201959B (en) | 2003-05-28 |
AU783118B2 (en) | 2005-09-29 |
NZ517928A (en) | 2004-09-24 |
WO2001022990A2 (fr) | 2001-04-05 |
EP1220684B1 (fr) | 2006-07-19 |
ES2265980T5 (es) | 2010-12-28 |
WO2001022990A3 (fr) | 2001-10-04 |
EP1220684B2 (fr) | 2010-07-14 |
ATE333284T1 (de) | 2006-08-15 |
JP2003510290A (ja) | 2003-03-18 |
AU7619000A (en) | 2001-04-30 |
EP1220684A2 (fr) | 2002-07-10 |
DE60029460D1 (de) | 2006-08-31 |
CA2386019C (fr) | 2011-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL148844A0 (en) | Methods related to immunostimulatory nucleic acid-induced interferon | |
AU7621600A (en) | Human rnase h and oligonucleotide compositions thereof | |
UA88457C2 (ru) | Иммуностимулирующая нуклеиновая кислота с улучшенной иммуностимулирующей эффективностью | |
DK1512686T3 (da) | Imidazonaphtyridiner og deres anvendelse til at inducere cytokinbiosyntese | |
AU4306896A (en) | Method for the preparation of a viral vector by intermolecular homologous recombination | |
WO2003086280A3 (fr) | Oligoribonucleotides immunostimulants contenant de la guanine et de l'uracile | |
CO5280045A1 (es) | Nueva composicion | |
EP1820853A3 (fr) | Virus de la grippe recombinant pour vaccins et thérapie génétique | |
NZ503830A (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
MY122383A (en) | Cyclic boroproline compounds | |
MXPA04011937A (es) | Oligonucleotidos inmunoestimuladores y sus usos. | |
WO1999046366A8 (fr) | Utilisations de cellules souches humaines mesenchymateuses non autologues | |
ATE320435T1 (de) | Oxazolo-, thiazolo- und selenazolo-(4,5- c)naphthyridin-4-amine und analoge davon | |
PL351893A1 (en) | Vaccines | |
PL356846A1 (en) | Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase | |
MXPA02007899A (es) | Citoquinas modificadas para utilizarse en terapia de cancer. | |
IL155514A0 (en) | Fusion cells and cytokine compositions for treatment of disease | |
EP1762614A3 (fr) | Promoteurs spécifiques de tumeur | |
WO1999046371A3 (fr) | Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale | |
MXPA04001720A (es) | Acido nucleicos bv8 y polipeptidos con actividad mitogenica. | |
WO1999056784A3 (fr) | Utilisation d'un inhibiteur de nuclease ou de l'interleukine 10 (il-10) dans la preparation d'une composition therapeutique visant a ameliorer la transfection d'un polynucleotide dans une cellule, compositions utilisees en therapie genique | |
IL148360A0 (en) | A herpes viral mutant and pharmaceutical compositions containing the same | |
WO2003022225A3 (fr) | Compositions comprenant des melanges de proteines therapeutiques et leurs procedes de preparation | |
MY127452A (en) | Vaccines. | |
AU2001259744A1 (en) | Compositions and methods for producing antigen-presenting cells |